Electrophysiology Mapping and Ablation Devices – Market Insights – United States

The US EP mapping and ablation device market will experience strong growth through 2035, driven by the rapid expansion of AF ablation procedures, particularly PFA devices, and the approval of reimbursement for cardiac ablation procedures at ASCs in the US.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for EP mapping and ablation devices in the US from 2019 to 2035.

CMS reimbursement for EP ablation procedures conducted at ASCs will impact procedure volumes and ASPs across the US EP device market.

Which EP ablation procedures are expected to shift into the ASC setting following reimbursement approval?

How will the migration of EP ablation procedures to ASCs affect procedure volumes and ASPs?

To what extent will ASC expansion add additional EP ablation volumes versus transfer volumes occurring at hospitals over to ASCs?

Rising AF ablation procedures will continue to drive growth across several segments of the EP mapping and ablation market.

How have AF ablation procedure volumes shifted in the US, and which device approvals have supported growth?

What are the different levels of growth seen in paroxysmal AF and persistent AF ablation procedure volumes?

What are the subsequent downstream impacts of rising AF ablation volumes on associated devices?

Recent clinical guidelines will support the adoption of cardiac ablation procedures.

What changes have been made in the latest clinical guidelines regarding the use of cardiac ablation for treating cardiac arrhythmias?

How will the recent clinical guideline updates influence physicians’ opinions on ablation techniques for treating cardiac arrhythmias, particularly AF?

How will recent approvals for EP ablation procedures in ASCs impact future procedure trends?